PPAR-β/δ agonists for type 2 diabetes and dyslipidemia: An adopted orphan still looking for a home

Expert Opinion on Investigational Drugs

Volumn 17, Issue 10, 2008, Pages 1465-1471

  Billin, Andrew N ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Agonist; GW501516; GW590735; KD 3010; MBX 8025

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; AGENTS AFFECTING LIPID METABOLISM; ATORVASTATIN; GW 590735; ISOPROSTANE DERIVATIVE; KD 3010; MBX 8025; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PLACEBO; RWJ 800025; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FATTY ACID OXIDATION; GLUCOSE HOMEOSTASIS; HEART FAILURE; HUMAN; INSULIN RESISTANCE; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN DEGRADATION; REVIEW; THERAPY EFFECT;

ANIMALS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GLUCOSE; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS; PPAR DELTA; PPAR-BETA; PROPIONIC ACIDS; THIAZOLES;

EID: 52949099182     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.10.1465     Document Type: Review

References (38)

1. Reilly SM, Lee CH. PPAR-delta as a therapeutic target in metabolic disease. FEBS Lett 2008;582:26-31
2. Takahashi S, Tanaka T, Sakai J. New therapeutic target for metabolic syndrome: PPAR-delta. Endocr J 2007;54:347-57
3. Seedorf U, Aberle J. Emerging roles of PPAR-delta in metabolism. Biochim Biophys Acta 2007;1771:1125-31
4. Kang K, Hatano B, Lee CH. PPAR delta agonists and metabolic diseases. Curr Atheroscler Rep 2007;9:72-7
5. Furnsinn C, Willson TM, Brunmair B. Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 2007;50:8-17
6. Takahashi S, Tanaka T, Kodama T, Sakai J. Peroxisome proliferator-activated receptor delta (PPAR-delta), a novel target site for drug discovery in metabolic syndrome. Pharmacol Res 2006;53:501-7
7. Barish GD, Narkar VA, Evans RM. PPAR-delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006;116:590-7
8. Berger J, Leibowitz MD, Doebber TW, et al. Novel peroxisome proliferator-activated receptor (PPAR)-gamma and PPAR-delta ligands produce distinct biological effects. J Biol Chem 1999;274:6718-25
9. Leibowitz MD, Fievet C, Hennuyer N, et al. Activation of PPAR-delta alters lipid metabolism in db/db mice. FEBS Lett 2000;473:333-6
10. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50
11. Oliver WR Jr, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001;98:5306-11
12. Wallace JM, Schwarz M, Coward P, et al. Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 2005;46:1009-16
13. Lee CH, Chawla A, Urbiztondo N, et al. Transcriptional repression of atherogenic infl ammation: modulation by PPAR-delta. Science 2003;302:453-7
14. Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR-alpha, beta/delta, and gamma. J Clin Invest 2004;114:1564-76
15. Vosper H, Khoudoli GA, Palmer CN. The peroxisome proliferator activated receptor delta is required for the differentiation of THP-1 monocytic cells by phorbol ester. Nucl Recept 2003;1:9
16. Graham TL, Mookherjee C, Suckling KE, et al. The PPAR-delta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 2005;181:29-37
17. Barish GD, Atkins AR, Downes M, et al. PPAR-delta regulates multiple proinfl ammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci USA 2008;105:4271-6
18. Takata Y, Liu J, Yin F, et al. PPAR-delta-mediated anti-inflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci USA 2008;105:4277-82
19. Kilgore KS, Billin AN. PPAR-beta/delta ligands as modulators of the inflammatory response. Curr Opin Investig Drugs 2008;9:463-9
20. Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 2003;100:15924-9
21. Lee CH, Olson P, Hevener A, et al. PPAR-delta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006;103:3444-9
22. Cheng L, Ding G, Qin Q, et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004;10:1245-50
23. Burkart EM, Sambandam N, Han X, et al. Nuclear receptors PPAR-beta/delta and PPAR-alpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 2007;117:3930-9
24. Planavila A, Rodriguez-Calvo R, Jove M, et al. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 2005;65:832-41
25. Ding G, Cheng L, Qin Q, et al. PPAR-delta modulates lipopolysaccharide-induced TNF-alpha infl ammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 2006;40:821-8
26. Jucker BM, Doe CP, Schnackenberg CG, et al. PPAR-delta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure. J Cardiovasc Pharmacol 2007;50:25-34
27. Sprecher DL, Massien C, Pearce G, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator-activated receptor delta agonist. Arterioscler Thromb Vasc Biol 2007;27:359-65
28. Sprecher DL, Johnson A, Pearce G, Watts G, Barrett P. Lipid and lipoprotein metabolism: clinical 2. Effects of a peroxisome proliferator activated receptor (PPAR) delta agonist on apolipoprotein B-100 kinetics in the metabolic syndrome [presentation number 1211; session number AOP.15.2]. American Heart Association Scientific Sessions 2005
29. Riserus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008;57:332-9
30. Guha M, Deng M, Duron S, et al. Selective activation of peroxisome proliferator-activated receptor β/δ holds promise for the treatment of obesity, metabolic syndrome and diabesity. Available from: http://www.kalypsys.com/media/presentations/PPAR%202006%20ADA.pdf [Last accessed July 2008]
31. Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771:1065-81
32. Shearer BG, Billin AN. The next generation of PPAR drugs: do we have the tools to fi nd them? Biochim Biophys Acta 2007;1771:1082-93
33. Howes LG, Kostner K. The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin Investig Drugs 2007;16:1509-16
34. Schmuth M, Jiang YJ, Dubrac S, et al. Peroxisome proliferator-activated receptors (PPAR) and liver X receptors (LXR) in epidermal biology. J Lipid Res 2008;49(3):499-509
35. Michalik L, Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 2007;1771:991-8
36. Kim DJ, Bility MT, Billin AN, et al. PPAR-beta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ 2006;13:53-60
37. Kim DJ, Murray IA, Burns AM, et al. Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem 2005;280:9519-27
38. De La Monte SM, Tong M, Lester-Coll N, et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis 2006;10:89-109